Captrust Financial Advisors Has $284,000 Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Captrust Financial Advisors grew its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 48.4% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 15,786 shares of the company’s stock after buying an additional 5,146 shares during the period. Captrust Financial Advisors’ holdings in Teva Pharmaceutical Industries were worth $284,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Sequoia Financial Advisors LLC grew its position in Teva Pharmaceutical Industries by 0.7% during the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock worth $2,025,000 after buying an additional 805 shares in the last quarter. Smithfield Trust Co grew its holdings in shares of Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares in the last quarter. Signaturefd LLC increased its position in shares of Teva Pharmaceutical Industries by 16.9% during the third quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock valued at $137,000 after purchasing an additional 1,094 shares during the period. Bridgewater Associates LP raised its stake in shares of Teva Pharmaceutical Industries by 5.2% in the third quarter. Bridgewater Associates LP now owns 23,222 shares of the company’s stock valued at $418,000 after purchasing an additional 1,144 shares in the last quarter. Finally, United Services Automobile Association lifted its position in Teva Pharmaceutical Industries by 3.1% in the second quarter. United Services Automobile Association now owns 41,159 shares of the company’s stock worth $669,000 after purchasing an additional 1,249 shares during the period. Institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on TEVA. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Finally, StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average price target of $19.67.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. The trade was a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 1.8 %

TEVA stock opened at $16.50 on Friday. The business has a fifty day moving average price of $17.49 and a 200 day moving average price of $17.39. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. Teva Pharmaceutical Industries Limited has a fifty-two week low of $9.90 and a fifty-two week high of $19.31. The stock has a market capitalization of $18.69 billion, a price-to-earnings ratio of -19.41, a P/E/G ratio of 1.04 and a beta of 0.79.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.